

Special Issue

Antibiotic Susceptibility Testing Guides Clinical Treatment Decisions: From Empiric to Targeted Therapy

Message from the Guest Editors

Antibiotic resistance remains a global health challenge, reducing the effectiveness of both empiric and targeted therapies. Effective infectious disease management increasingly relies on collaboration between clinical microbiologists, infectologists, and treating physicians. While antimicrobial susceptibility testing (AST) provides essential data on pathogen susceptibility, its clinical value lies in expert interpretation linking laboratory results to therapeutic decisions.

This Special Issue will highlight the critical interface between microbiology and clinical care, emphasizing the importance of teamwork in selecting appropriate antibiotics and shifting from empiric to individualized therapy.

We welcome contributions on advancements in AST methods, interpretation strategies, and case reports that demonstrate the role of microbiological examination in optimizing treatment and supporting antimicrobial stewardship. Submissions addressing infection-related mortality, the application of novel therapeutic options, and the clinical outcomes of susceptibility-guided therapy are also encouraged.

Guest Editors

Dr. Jan Závora
Dr. Simona Arientová
Dr. Christopher K. C. Lai

Deadline for manuscript submissions

31 December 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/249592

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)